Nuvalent (NUVL) Return on Capital Employed Growth (3y) (2024 - 2026)

Nuvalent (NUVL) Return on Capital Employed Growth (3y) (2024 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE Growth (3y) (Qtr)
1 Oculis Holding AG 65,899.61 Bn 65,899.33 Bn - -
2 Nanobiotix 1,933.82 Bn 1,933.76 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 471.67 Bn 466.88 Bn 1.35 Bn 4,893.00
5 Vertex Pharmaceuticals 122.32 Bn 115.07 Bn 2.59 Bn -494.00
6 Regeneron Pharmaceuticals 70.04 Bn 61.29 Bn 3.31 Bn -649.00
7 Belite Bio 62.06 Bn 62.06 Bn - -
8 Argenx Se 55.93 Bn 50.74 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.55 Bn 34.54 Bn 959.66 Mn 4,853.00
10 Nuvalent 9.75 Bn 9.75 Bn - -1,231.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -1,231.00
Dec 31, 2025 -1,264.00
Sep 30, 2025 -1,276.00
Jun 30, 2025 -1,080.00
Mar 31, 2025 -1,008.00
Dec 31, 2024 -954.00
Sep 30, 2024 -1,193.00